PDL BioPharma, Inc. PDLI

Other  —  Other
Market cap
—
P/E
0.0×
Older periods Dec '19 Mar '20 Jun '20 Dec '20
ROE

+8 more TTM periods

(10.64%) (17.45%) (28.44%) —
ROA
(8.38%) (13.74%) (21.88%) 0.00%
ROIC
(13.82%) (17.50%) (24.38%) —
Return on Tangible Assets
(26.00%) (21.22%) (33.39%) —
Average Days of Receivables
43.72 53.11 43.36 —
Free Cash Flow per Share
0.59 (0.38) (0.06) —
Free Cash Flow
70.29 (46.21) (6.85) —
Capital Expenditures
102.73 (0.81) 81.74 —
Piotroski F-Score
2.00 3.00 3.00 —
Other line items
Cash ROIC
(4.11%) (6.56%) (16.44%) —
Accounts Receivable Turnover
3.88 4.58 4.31 —
Accounts Payable Turnover
6.78 5.97 5.50 —
Inventory Turnover
3.97 4.04 3.49 —
Average Days of Payables
18.21 36.23 25.53 —
Days of Inventory on Hand
54.87 73.04 91.51 —
Tax Rate
(0.04) (0.15) (0.13) —
Research and Development Expense of Revenue
13.35% 15.27% 17.05% —
Selling, General and Administrative Expense of Revenue
98.76% 107.87% 113.32% —
Share Based Compensation of Revenue
13.00% 43.98% 42.29% —
Interest Coverage
0.00 0.00 0.00 —
Operating CF/Net income
0.46 0.42 0.57 —
Depreciation/Fixed assets
6.80 4.75 4.41 —
Capex/Depreciation
5.90 (0.05) 6.10 —
Revenue per Share
0.46 0.44 0.45 —
Operating CF per Share
(0.27) (0.37) (0.76) —
Capex per Share
0.87 (0.01) 0.71 —
Capex to Sales
(1.88) 0.02 (1.58) —
Net Profit Margin
(128.59%) (201.30%) (297.95%) —

Fold the line items

Columns are period end dates